Semaglutide vs Tirzepatide
How the two most prescribed weight-management drugs differ: what they act on, what each is approved for, and what the one head-to-head trial found.
Side-by-side facts · No recommendation · Reviewed
SemaglutideTirzepatideSame for both
| Semaglutide | Tirzepatide | |
|---|---|---|
| Acts on | GLP-1 receptor | GIP and GLP-1 receptors |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Approved for | Type 2 diabetes; chronic weight management | Type 2 diabetes; chronic weight management; obstructive sleep apnea in people with obesity |
| Forms | Weekly injection; daily tablets | Weekly injection |
| Boxed warning | BothThyroid C-cell tumors (rodent data) | |
The head-to-head trial
SURMOUNT-5 compared the two directly in 751 adults with obesity and no diabetes, each on the highest dose they tolerated, for 72 weeks. Results were published in the New England Journal of Medicine in 2025.
Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. 64.6% of people on tirzepatide lost at least 15% of their body weight, compared with 40.1% on semaglutide. Waist size fell by 18.4 cm and 13.0 cm.
The trial was open-label, so participants knew which drug they were on, and it was sponsored by Eli Lilly, which makes tirzepatide. Most side effects were stomach and bowel symptoms, mostly mild to moderate, and mostly while the dose was being raised.
Key differences
Tirzepatide acts on two hormone receptors, GIP and GLP-1. Semaglutide acts on GLP-1 only.
Semaglutide is also available as a tablet. Tirzepatide is injection only.
Tirzepatide carries an additional approval for obstructive sleep apnea in people with obesity.
What they share
Both are weekly injections approved by FDA, both carry the same boxed warning about thyroid C-cell tumors seen in rodents, and both list nausea, vomiting, diarrhea, constipation and stomach pain as the most common side effects. Labels for the class also warn about pancreatitis.
Questions
Is tirzepatide stronger than semaglutide?
In the SURMOUNT-5 head-to-head trial, average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. Which drug suits a person is a decision for them and their prescriber.
Can you switch from semaglutide to tirzepatide?
Switching is a prescribing decision. A prescriber sets the new starting dose and schedule. This site does not recommend doses.
Do they have the same side effects?
Broadly, yes. Both list stomach and bowel symptoms as the most common side effects and carry the same boxed warning about thyroid C-cell tumors seen in rodents.
Which compound, if any, suits a person is a decision for them and a licensed prescriber. This page compares published facts and does not recommend either.
Sources: ACC: SURMOUNT-5 journal scan; Eli Lilly: SURMOUNT-5 detailed results; Weill Cornell Medicine: head-to-head trial; Managed Healthcare Executive: GLP-1 pills; Prime Therapeutics: GLP-1 pipeline update, August 2026; Novo Nordisk: Wegovy and Saxenda safety information; Polsinelli: FDA compounded GLP-1 policy; Managed Healthcare Executive: GLP-1 pills; Prime Therapeutics: GLP-1 pipeline update, August 2026; Polsinelli: FDA compounded GLP-1 policy.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.